The estimated Net Worth of Mario Eisenberger is at least $145 Tisíc dollars as of 15 August 2022. Mario Eisenberger owns over 100,000 units of Veru Inc stock worth over $87,000 and over the last 6 years he sold VERU stock worth over $0. In addition, he makes $57,673 as Independent Director at Veru Inc.
Sign up
Mario Eisenberger VERU stock SEC Form 4 insiders trading
Mario has made over 1 trades of the Veru Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 100,000 units of VERU stock worth $157,000 on 15 August 2022.
The largest trade he's ever made was exercising 100,000 units of Veru Inc stock on 15 August 2022 worth over $157,000. On average, Mario trades about 8,333 units every 0 days since 2018. As of 15 August 2022 he still owns at least 100,000 units of Veru Inc stock.
You can see the complete history of Mario Eisenberger stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mario Eisenberger biography
Dr. Mario Eisenberger M.D. serves as Independent Director of the Company. He has served as director of the Company since October 2016. Dr. Eisenberger currently is the Dale Hughes Professor of Oncology at The Johns Hopkins University and has been in the full-time faculty since 1993. From 2010 to 2014, Dr. Eisenberger founded Oncology Trials Insights, Inc., a privately held clinical trials management company. Since 2010, Dr. Eisenberger has also served as an ad-hoc member of the Oncologic Drugs Advisory Committee of the FDA. Since 1988, he has served in advisory, strategic and data safety monitoring boards, including Bristol-Myers Squibb, Sanofi, Astellas, Schering Plough, Auguron, AKZO, Dupont, Rhone-Poulenc Rorer, Aventis, Jansen, Ipsen, Active Biotech, Medivation, Tokai, Xanthus, Cytogen, Ortho Biotech, Active Biotech, Merck-Sharp and Dohme, Tyme, Inc., Ferring and Bayer. From 1984 to 1998, Dr. Eisenberger held the position of head of the advanced prostate cancer committee and vice chair of the genitourinary cancer of the Southwest Oncology Group. From 1984 to 1993, he served as Professor of Oncology at The University of Maryland. From 1984 to 1989, he was the Chief of Oncology at the Baltimore VAH. From 1982 to 1984, he was a Senior Investigator at the Cancer Therapy Evaluation Program of the National Institute in charge of coordinating extramural clinical research in urological cancers. From 1976 to 1982, he served in the faculty of the University of Miami. Dr. Eisenberger obtained his M.D. at the Federal University of Rio de Janeiro Brazil in 1972 and is board certified in Internal Medicine and Medical Oncology.
What is the salary of Mario Eisenberger?
As the Independent Director of Veru Inc, the total compensation of Mario Eisenberger at Veru Inc is $57,673. There are 10 executives at Veru Inc getting paid more, with Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D. having the highest compensation of $1,426,295.
How old is Mario Eisenberger?
Mario Eisenberger is 70, he's been the Independent Director of Veru Inc since 2016. There are no older and 13 younger executives at Veru Inc.
What's Mario Eisenberger's mailing address?
Mario's mailing address filed with the SEC is 2916 N. MIAMI AVENUE, SUITE 1000, MIAMI, FL, 33127.
Insiders trading at Veru Inc
Over the last 7 years, insiders at Veru Inc have traded over $5,672,221 worth of Veru Inc stock and bought 673,267 units worth $1,199,518 . The most active insiders traders include Mitchell Shuster Steiner, Harry Fisch a K Gary Barnette. On average, Veru Inc executives and independent directors trade stock every 33 days with the average trade being worth of $22,682. The most recent stock trade was executed by Harry Fisch on 24 May 2024, trading 4,000 units of VERU stock currently worth $5,000.
What does Veru Inc do?
the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries
What does Veru Inc's logo look like?
Complete history of Mario Eisenberger stock trades at Veru Inc
Veru Inc executives and stock owners
Veru Inc executives and other stock owners filed with the SEC include:
-
Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D.,
Chairman, Pres & CEO -
Dr. Mitchell S. Steiner F.A.C.S., M.D., F.A.C.S,
Chairman, Pres & CEO -
Mitchell Steiner,
Chairman of the Board, President, Chief Executive Officer -
Dr. Harry Fisch F.A.C.S., M.D.,
Vice Chairman & Chief Corp. Officer -
K Barnette,
Chief Scientific Officer -
Michele Greco,
Chief Financial Officer, Chief Administrative Officer -
Dr. K. Gary Barnette Ph.D.,
Chief Scientific Officer -
Dr. Harry Fisch,
Vice Chairman & Chief Corp. Officer -
Harry Fisch,
Vice Chairman of the Board, Chief Corporate Officer -
Michele Greco,
CFO & Chief Admin. Officer -
Mario Eisenberger,
Independent Director -
Jesus Socorro,
Independent Director -
Michael Rankowitz,
Independent Director -
Joel Batten,
Exec. VP & GM of Infectious Disease Franchise -
Dr. Gary Bird Ph.D.,
Exec. VP of Quality & Regulatory Affairs -
Dr. Domingo Rodriguez M.D.,
Exec. VP of Global Clinical Operations -
Phillip Kuhn,
Exec. VP of Strategy & Commercial -
Philip R. Greenberg,
Exec. VP & Gen. Deputy Counsel -
Dr. Robert H. Getzenberg Ph.D.,
Exec. VP for Medical Affairs -
Kevin J. Gilbert CPA, J.D.,
Exec. VP of Corp. Devel. -
Michael J. Purvis,
Exec. VP, Gen. Counsel & Corp. Strategy -
Samuel Fisch,
Exec. Director of Investor Relations & Corp. Communications -
Loren Mark Katzovitz,
Director -
Brian J. Groch,
Chief Commercial Officer -
Daniel Haines,
Chief Financial Officer -
Grace Hyun,
Director -
Charles T Jr Todd,
CEO of FHC Division -
O B Parrish,
Director -
Lucy Lu,
Director -
Robert Getzenberg,
Chief Scientific Officer -
Mary Margaret Frank,
Director -
David R Bethune,
Director